DK0560932T3 - - Google Patents

Info

Publication number
DK0560932T3
DK0560932T3 DK92902782.9T DK92902782T DK0560932T3 DK 0560932 T3 DK0560932 T3 DK 0560932T3 DK 92902782 T DK92902782 T DK 92902782T DK 0560932 T3 DK0560932 T3 DK 0560932T3
Authority
DK
Denmark
Prior art keywords
gene
products
neu
expression
pct
Prior art date
Application number
DK92902782.9T
Other languages
Danish (da)
English (en)
Inventor
Mien-Chie Hung
Di-Hua Yu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK0560932T3 publication Critical patent/DK0560932T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK92902782.9T 1990-12-04 1991-12-04 DK0560932T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62146590A 1990-12-04 1990-12-04

Publications (1)

Publication Number Publication Date
DK0560932T3 true DK0560932T3 (cg-RX-API-DMAC7.html) 1997-02-17

Family

ID=24490270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92902782.9T DK0560932T3 (cg-RX-API-DMAC7.html) 1990-12-04 1991-12-04

Country Status (11)

Country Link
US (1) US5651964A (cg-RX-API-DMAC7.html)
EP (1) EP0560932B1 (cg-RX-API-DMAC7.html)
JP (2) JPH06504671A (cg-RX-API-DMAC7.html)
AT (1) ATE142261T1 (cg-RX-API-DMAC7.html)
AU (1) AU651650B2 (cg-RX-API-DMAC7.html)
CA (1) CA2096723C (cg-RX-API-DMAC7.html)
DE (1) DE69121903T2 (cg-RX-API-DMAC7.html)
DK (1) DK0560932T3 (cg-RX-API-DMAC7.html)
ES (1) ES2093248T3 (cg-RX-API-DMAC7.html)
GR (1) GR3021805T3 (cg-RX-API-DMAC7.html)
WO (1) WO1992010573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US6861506B1 (en) 1996-01-11 2005-03-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
CA2250222A1 (en) * 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0013814A (pt) 1999-08-27 2002-04-23 Genentech Inc Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
US20040086903A1 (en) * 2000-12-29 2004-05-06 Jean-Jacques Lareyre Epididymal lipocalin gene and uses thereof
US20020169126A1 (en) * 2001-03-21 2002-11-14 Mien-Chie Hung Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
PT2247297T (pt) * 2008-01-31 2019-04-24 Univ Vanderbilt Tratamento terapêutico para estados pulmonares
HUE045571T2 (hu) 2008-01-31 2020-01-28 Univ Vanderbilt Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
ES2067755T3 (es) * 1989-06-22 1995-04-01 Vestar Inc Proceso de encapsulado.
ATE237694T1 (de) * 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy

Also Published As

Publication number Publication date
DE69121903D1 (de) 1996-10-10
CA2096723C (en) 2006-03-28
EP0560932A1 (en) 1993-09-22
AU651650B2 (en) 1994-07-28
ATE142261T1 (de) 1996-09-15
CA2096723A1 (en) 1992-06-05
JP2002114707A (ja) 2002-04-16
JP3323491B2 (ja) 2002-09-09
WO1992010573A1 (en) 1992-06-25
JPH06504671A (ja) 1994-06-02
AU9146991A (en) 1992-07-08
ES2093248T3 (es) 1996-12-16
GR3021805T3 (en) 1997-02-28
US5651964A (en) 1997-07-29
DE69121903T2 (de) 1997-04-10
EP0560932B1 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
DK0560932T3 (cg-RX-API-DMAC7.html)
EP1064952A3 (en) Methods and compositions for the suppression of neu mediated transformations
Christl et al. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis
Scheppach et al. Role of short-chain fatty acids in the prevention of colorectal cancer
Easty et al. Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck
Nishihira et al. Molecular and cellular features of esophageal cancer cells
Vielkind Genetic control of cell differentiation in platyfish‐swordtail melanomas
Russo et al. Development pattern of human breast and susceptibility to carcinogenesis
Tatematsu et al. Independent induction of intestinal metaplasia and gastric cancer in rats treated with N-methyl-N′-nitro-N-nitrosoguanidine
WO2002006526A8 (en) Detection of copy number changes in colon cancer
PL354334A1 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
Thalmann et al. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
Easty et al. Five human tumour cell lines derived from a primary squamous carcinoma of the tongue, two subsequent local recurrences and two nodal metastases
Timmons et al. Expression of galectin-7 during epithelial development coincides with the onset of stratification
Schmidt et al. Gastrointestinal cancer studies in the human to nude mouse heterotransplant system
Castle et al. High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum-and anchorage-independent growth.
Blagosklonny Cell immortality and hallmarks of cancer
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
EP0526649A4 (en) Carboxymethylmannoglucan and derivative thereof
Russo et al. Ape1/Ref-1 expression and cellular localization in human thyroid carcinoma cell lines
Wang et al. The in vitro effect of vitamin D3 analogue EB‐1089 on a human prostate cancer cell line (PC‐3)
Thijssen et al. Local aromatase activity in human breast tissues
Niendorf et al. Effect of 1, 25-dihydroxyvitamin D3 on human cancer cells in vitro
Nishi et al. Stimulation of growth by both androgen and estrogen of the EMP-K1 transplantable tumor with androgen and estrogen receptors from human extramammary Paget's disease in nude mice